The many layers of epigenetic dysfunction in B-cell lymphomas

Area of Science:

• Oncology
• Epigenetics
• Hematology

Background:

• Epigenetic deregulation is increasingly recognized as a critical factor in the development of B-cell lymphomas.
• Understanding these epigenetic changes is crucial for deciphering lymphoma biology and clinical behavior.

Purpose of the Study:

• To review how alterations in DNA methylation, histone modifications, and other epigenetic mechanisms contribute to the pathogenesis of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.
• To explain the impact of epigenetic perturbations on the biology and clinical features of these hematologic malignancies.

Main Methods:

• Review of current literature on epigenetics in lymphoma.
• Analysis of key findings related to DNA methylation and histone modification mutations in DLBCL and follicular lymphoma.

Main Results:

• DNA methylation heterogeneity is a central feature of DLBCL, associated with poor outcomes and relapse.
• Somatic mutations in histone modifier genes (e.g., EZH2, KMT2D) establish aberrant histone modification patterns, driving lymphomagenesis.
• Activation-induced cytosine deaminase contributes to epigenetic diversity in B-cell lymphomas.

Conclusions:

• Epigenetic insights are shifting the understanding of lymphoma clonal heterogeneity and phenotype.
• Altered epigenetic landscapes, particularly at gene promoters and enhancers, are critical for lymphoma development.
• This evolving understanding is paving the way for novel therapeutic strategies for DLBCL and follicular lymphoma.